We are committed to finding a safe, effective, and patient-friendly therapy for food and pediatric allergy patients

 

OLFUS-VIPES Results

Latest News

DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age 

DBV Technologies Reports First Half 2017 Financial Results

Documentation

20F- Form 2016

Agenda

Citi’s 12th Annual Biotech Conference

Boston, MA, USA